Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
Milind Javle, Mitesh J. Borad, Nilofer S. Azad, Razelle Kurzrock, Ghassan K. Abou-Alfa, Ben George, John Hainsworth, Funda Meric-Bernstam, Charles Swanton, Christopher J. Sweeney, Claire F. Friedman, Ron Bose, David R. Spigel, Yong Wang, Jonathan Levy, Katja Schulze, Vaikunth Cuchelkar, Arisha Patel, Howard Burris
Dive into the research topics of 'Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study'. Together they form a unique fingerprint.